GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS)
CNY 12.03
(-0.66%)
CNY 12.03
(-0.66%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 369.18 Million CNY | 20.54% |
| 2022 | 243.99 Million CNY | 29.01% |
| 2021 | 191.58 Million CNY | 62.65% |
| 2020 | 112.97 Million CNY | -26.77% |
| 2019 | 159.72 Million CNY | 19.05% |
| 2018 | 138.02 Million CNY | 42.75% |
| 2017 | 95.19 Million CNY | -0.45% |
| 2016 | 91.1 Million CNY | 54.45% |
| 2015 | 63.59 Million CNY | 72.2% |
| 2014 | 34.74 Million CNY | 30.52% |
| 2013 | 19.84 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 93.6 Million CNY | -1.8% |
| 2024 Q1 | 73.37 Million CNY | -48.72% |
| 2024 Q2 | 87.78 Million CNY | 14.9% |
| 2023 Q3 | 67.9 Million CNY | 34.16% |
| 2023 Q4 | 110.95 Million CNY | 63.4% |
| 2023 FY | - CNY | 20.54% |
| 2023 Q1 | 64.62 Million CNY | -46.05% |
| 2023 Q2 | 50.61 Million CNY | -21.67% |
| 2022 Q2 | 55.71 Million CNY | 223.67% |
| 2022 Q1 | 17.21 Million CNY | -64.44% |
| 2022 FY | - CNY | 29.01% |
| 2022 Q4 | 119.78 Million CNY | 161.56% |
| 2022 Q3 | 45.79 Million CNY | -17.81% |
| 2021 Q4 | 48.41 Million CNY | -0.06% |
| 2021 FY | - CNY | 62.65% |
| 2021 Q2 | 73.21 Million CNY | 352.13% |
| 2021 Q1 | 16.19 Million CNY | -70.28% |
| 2021 Q3 | 48.44 Million CNY | -33.83% |
| 2020 Q4 | 54.48 Million CNY | 1466.97% |
| 2020 FY | - CNY | -26.77% |
| 2020 Q2 | 22.77 Million CNY | -28.56% |
| 2020 Q1 | 31.87 Million CNY | -36.8% |
| 2020 Q3 | 3.47 Million CNY | -84.73% |
| 2019 Q1 | 25.21 Million CNY | 0.0% |
| 2019 FY | - CNY | 19.05% |
| 2019 Q4 | 50.43 Million CNY | 15.79% |
| 2019 Q3 | 43.55 Million CNY | 14.27% |
| 2019 Q2 | 38.11 Million CNY | 51.15% |
| 2018 FY | - CNY | 42.75% |
| 2018 Q2 | 36.36 Million CNY | 145.71% |
| 2018 Q1 | 14.79 Million CNY | -51.52% |
| 2017 FY | - CNY | -0.45% |
| 2017 Q1 | 13.34 Million CNY | -34.6% |
| 2017 Q3 | 30.52 Million CNY | 0.0% |
| 2017 Q4 | 30.52 Million CNY | 0.0% |
| 2016 Q4 | 20.4 Million CNY | 0.0% |
| 2016 Q1 | 17.65 Million CNY | 14.19% |
| 2016 Q2 | 17.65 Million CNY | -0.0% |
| 2016 Q3 | 20.4 Million CNY | 15.57% |
| 2016 FY | - CNY | 54.45% |
| 2015 Q3 | 15.46 Million CNY | 35.73% |
| 2015 Q1 | 11.39 Million CNY | 16.9% |
| 2015 Q4 | 15.46 Million CNY | 0.0% |
| 2015 Q2 | 11.39 Million CNY | -0.0% |
| 2015 FY | - CNY | 72.2% |
| 2014 Q3 | 9.74 Million CNY | 27.82% |
| 2014 Q1 | 7.62 Million CNY | 0.0% |
| 2014 FY | - CNY | 30.52% |
| 2014 Q2 | 7.62 Million CNY | -0.0% |
| 2014 Q4 | 9.74 Million CNY | 0.0% |
| 2013 FY | - CNY | 0.0% |